Coya Therapeutics Updates Business Address in Houston

TL;DR

**Coya Therapeutics just moved offices, no big deal for the stock.**

AI Summary

Coya Therapeutics, Inc. filed an 8-K on January 19, 2024, to update its business address from 12645 Memorial Dr., Suite F1 #305, Houston, TX 77024 to 5850 San Felipe St., Suite 500, Houston, TX 77057. This change is a routine administrative update and does not signal any operational shifts or financial impacts. For investors, this simply means the company's physical location has moved, which is generally not a material event affecting stock value.

Why It Matters

This filing is a routine administrative update regarding Coya Therapeutics' physical location and does not indicate any changes to its operations, financial health, or strategic direction.

Risk Assessment

Risk Level: low — The filing reports a simple change of business address, which carries no inherent financial or operational risk.

Analyst Insight

Smart investors would recognize this as a purely administrative update with no material impact on Coya Therapeutics' business fundamentals or stock price, thus requiring no immediate action.

Key Players & Entities

• Coya Therapeutics, Inc. (company) — the registrant filing the 8-K
• 12645 Memorial Dr., Suite F1 #305, Houston, TX 77024 (address) — Coya Therapeutics' former business address
• 5850 San Felipe St., Suite 500, Houston, Texas 77057 (address) — Coya Therapeutics' new business address
• January 19, 2024 (date) — date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — ich Registered Common Stock, par value $0.0001 per share COYA The Nasdaq Stock Mar
• $32.6 million — ash and cash equivalents (unaudited) of $32.6 million. In January 2024, the Company received
• $7.5 million — . In January 2024, the Company received $7.5 million from Dr. Reddy's Laboratories Ltd. ("Dr
• $40.1 million — received on December 31, 2023) would be $40.1 million. In addition, as previously disclosed i
• $4.2 m — dy's will pay the Company an additional $4.2 million, and (ii) upon dosing of the firs
• $4.2 million — dy's will pay the Company an additional $4.2 million. The Company anticipates that the IND f

Filing Documents

• d732822d8k.htm (8-K) — 26KB
• 0001193125-24-010775.txt ( ) — 150KB
• coya-20240119.xsd (EX-101.SCH) — 3KB
• coya-20240119_lab.xml (EX-101.LAB) — 18KB
• coya-20240119_pre.xml (EX-101.PRE) — 11KB
• d732822d8k_htm.xml (XML) — 3KB

01

Item 8.01 Other Events. As of December 31, 2023, Coya Therapeutics, Inc. (the "Company") had cash and cash equivalents (unaudited) of $32.6 million. In January 2024, the Company received $7.5 million from Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's"), as required under the terms of the Development and License Agreement entered into with Dr. Reddy's on December 5, 2023, which was previously disclosed in our Current Report on Form 8-K filed with the Securities and Exchange Commission on December 6, 2023 (the "Form 8-K"). The Company's cash and cash equivalents as of December 31, 2023, pro forma for receipt of the $7.5 million from Dr. Reddy's (as if such amount was received on December 31, 2023) would be $40.1 million. In addition, as previously disclosed in the Form 8-K, (i) upon the first Food and Drug Administration (FDA) acceptance of an investigational new drug (IND) application for COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS), Dr. Reddy's will pay the Company an additional $4.2 million, and (ii) upon dosing of the first patient in the first Phase 2 trial of COYA 302 for the treatment of ALS in the United States, Dr. Reddy's will pay the Company an additional $4.2 million. The Company anticipates that the IND filing will be made in the first half of 2024 and the dosing of the first patient in the first Phase 2 trial of COYA 302 for the treatment of ALS in the United States will occur in the second half of 2024. The Company expects its cash and cash equivalents described above will be sufficient to meet its operating needs into 2026.

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "may," "can," "anticipate," "assume," "should," "indicate," "would," "believe," "contemplate," "expect," "seek," "estimate," "continue," "plan," "point to," "project," "predict," "could," "intend," "target," "potential," "will," or similar words and expressions of the future. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks associated with the Company's current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of the Company's ongoing and planned clinical trials and related data, the timing of announcements, updates and results of the Company's clinical trials and related data, the Company's ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of the Company's product candidates, competitive position, industry environment, potential market opportunities, and market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company's business in general, please refer to the Company's F

View Full Filing

View this 8-K filing on SEC EDGAR